ALSO NOTED: Medicines Company gets positive safety data; InterMune gains $10M payday; and much more...

> The Medicines Company announced that three late-stage safety trials of Cleviprex, an experimental drug for severe high blood pressure, met their specified objectives. Release

> InterMune has pocketed a $10 million milestone payment from its pact with Roche on an experimental hepatitis C therapy. Release

> Genentech has agreed to pay an unspecified amount for an entire oncology program for a target run by Amphora. Release

> Australia's pSivida has struck a licensing deal with Faber Research to develop pSivida's drug delivery technologies for infectious diseases and diseases of the ear. Faber receives exclusive rights to pSivida's technologies for diseases of the ear and for five specific infectious diseases. All costs of development will be born by Faber and its operating company Auritec Pharmaceuticals. Release

> Osiris Therapeutics has won the FDA's fast track status for its stem cell treatment for Crohn's Disease. Release

> India's Ranbaxy expressed an interest in bidding for Merck KGaA's generic drug unit. Report (WSJ sub. req.)

And Finally... Japanese scientists have developed a technique to gauge a person's thoughts by changes in the blood flow of his brain. Report 

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.